Spillover effects of restrictive drug formularies: A case study of PacifiCare in California

American Journal of Managed Care

Volumn 11, Issue 1, 2005, Pages 24-26

  Wang, Y Richard ^a,b   Pauly, Mark V ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULARY; DRUG MARKETING; DRUG PREFERENCE; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; LINEAR REGRESSION ANALYSIS; MEDICAID; MEDICAL PRACTICE; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CALIFORNIA; FORMULARIES; GATEKEEPING; MANAGED CARE PROGRAMS; OMEPRAZOLE; ORGANIZATIONAL CASE STUDIES; PHYSICIAN-PATIENT RELATIONS; SULFOXIDES;

EID: 12144267834     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Wang YR, Pauly MV, Lin YA. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary. Am J Manag Care. 2003;9:686-696.
2. Health Industries Research Center. National accounts: marketing challenges and opportunities for the mid 2000s. Santa Cruz, Calif: Health Industries Research Center; Fall/Winter 2001. Available at: www.hire.com. Accessed December 1, 2004.